Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Finished Goods (2016 - 2019)

Plus Therapeutics has reported Finished Goods over the past 9 years, most recently at $1.7 million for Q1 2019.

  • Quarterly Finished Goods fell 13.33% to $1.7 million in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Mar 2019, down 13.33% year-over-year, with the annual reading at $1.6 million for FY2018, 8.2% down from the prior year.
  • Finished Goods was $1.7 million for Q1 2019 at Plus Therapeutics, up from $1.6 million in the prior quarter.
  • Over five years, Finished Goods peaked at $2.5 million in Q4 2015 and troughed at $1.5 million in Q1 2015.
  • The 5-year median for Finished Goods is $1.8 million (2017), against an average of $1.9 million.
  • Year-over-year, Finished Goods crashed 33.92% in 2015 and then skyrocketed 50.79% in 2016.
  • A 5-year view of Finished Goods shows it stood at $2.5 million in 2015, then fell by 26.45% to $1.8 million in 2016, then fell by 2.14% to $1.8 million in 2017, then dropped by 8.2% to $1.6 million in 2018, then rose by 2.69% to $1.7 million in 2019.
  • Per Business Quant, the three most recent readings for PSTV's Finished Goods are $1.7 million (Q1 2019), $1.6 million (Q4 2018), and $1.7 million (Q3 2018).